Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1981 Jan;67(1):37–41. doi: 10.1172/JCI110030

Nitrofurantoin cytotoxicity. In vitro assessment of risk based on glutathione metabolism.

S P Spielberg, G B Gordon
PMCID: PMC371569  PMID: 7451657

Abstract

Nitrofurantoin, a commonly used urinary tract antiseptic, has been associated with idiosyncratic pulmonary and hepatic damage. We have used human lymphocytes in vitro to explore the biochemical basis of susceptibility to nitrofurantoin toxicity. The drug itself did not damage the cells as assessed by trypan blue dye exclusion. In the presence of a mouse hepatic microsomal drug-activating system, however, nitrofurantoin metabolites produced dose dependent toxicity to the lymphocytes. Inhibition of the enzyme epoxide hydrolase did not enhance toxicity; the metabolite thus does not appear to be a furan epoxide. Binding of reactive metabolites to cell macromolecules may lead directly to cell death, or in vivo, by acting as haptens to secondary immunologic responses. The metabolite caused a dose-dependent depletion of lymphocyte glutathione content. Cells from a patient with glutathione synthetase deficiency showed markedly enhanced nitrofurantoin toxicity. The findings suggest that glutathione plays a major role in protecting cells from nitrofurantoin-induced damage, and that studies of lymphocyte toxicity and glutathione metabolism in patients experiencing idiosyncratic reactions to nitrofurantoin may lead to elucidation of the biochemical and genetic basis of drug susceptibility.

Full text

PDF
37

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Black M., Rabin L., Schatz N. Nitrofurantoin-induced chronic active hepatitis. Ann Intern Med. 1980 Jan;92(1):62–64. doi: 10.7326/0003-4819-92-1-62. [DOI] [PubMed] [Google Scholar]
  2. Boyd M. R. Evidence for the Clara cell as a site of cytochrome P450-dependent mixed-function oxidase activity in lung. Nature. 1977 Oct 20;269(5630):713–715. doi: 10.1038/269713a0. [DOI] [PubMed] [Google Scholar]
  3. Boyd M. R., Stiko A. W., Sasame H. A. Metabolic activation of nitrofurantoin--possible implications for carcinogenesis. Biochem Pharmacol. 1979 Mar 1;28(5):601–606. doi: 10.1016/0006-2952(79)90142-4. [DOI] [PubMed] [Google Scholar]
  4. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  5. Martz F., Failinger C., 3rd, Blake D. A. Phenytoin teratogenesis: correlation between embryopathic effect and covalent binding of putative arene oxide metabolite in gestational tissue. J Pharmacol Exp Ther. 1977 Oct;203(1):231–239. [PubMed] [Google Scholar]
  6. Mitchell J. R., Jollows D. J. Progress in hepatology. Metabolic activation of drugs to toxic substances. Gastroenterology. 1975 Feb;68(2):392–410. [PubMed] [Google Scholar]
  7. Nebert D. W., Jensen N. M. The Ah locus: genetic regulation of the metabolism of carcinogens, drugs, and other environmental chemicals by cytochrome P-450-mediated monooxygenases. CRC Crit Rev Biochem. 1979;6(4):401–437. doi: 10.3109/10409237909105427. [DOI] [PubMed] [Google Scholar]
  8. Oesch F., Kaubisch N., Jerina D. M., Daly J. W. Hepatic epoxide hydrase. Structure-activity relationships for substrates and inhibitors. Biochemistry. 1971 Dec 21;10(26):4858–4866. doi: 10.1021/bi00802a005. [DOI] [PubMed] [Google Scholar]
  9. Sasame H. A., Boyd M. R. Superoxide and hydrogen peroxide production and NADPH oxidation stimulated by nitrofurantoin in lung microsomes: possible implications for toxicity. Life Sci. 1979 Mar 19;24(12):1091–1096. doi: 10.1016/0024-3205(79)90042-0. [DOI] [PubMed] [Google Scholar]
  10. Sharp J. R., Ishak K. G., Zimmerman H. J. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med. 1980 Jan;92(1):14–19. doi: 10.7326/0003-4819-92-1-14. [DOI] [PubMed] [Google Scholar]
  11. Spielberg S. P. Acetaminophen toxicity in human lymphocytes in vitro. J Pharmacol Exp Ther. 1980 May;213(2):395–398. [PubMed] [Google Scholar]
  12. Spielberg S. P., Garrick M. D., Corash L. M., Butler J. D., Tietze F., Rogers L., Schulman J. D. Biochemical heterogeneity in glutathione synthetase deficiency. J Clin Invest. 1978 Jun;61(6):1417–1420. doi: 10.1172/JCI109060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Spielberg S. P., Kramer L. I., Goodman S. I., Butler J., Tietze F., Quinn P., Schulman J. D. 5-oxoprolinuria: biochemical observations and case report. J Pediatr. 1977 Aug;91(2):237–241. doi: 10.1016/s0022-3476(77)80819-6. [DOI] [PubMed] [Google Scholar]
  14. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem. 1969 Mar;27(3):502–522. doi: 10.1016/0003-2697(69)90064-5. [DOI] [PubMed] [Google Scholar]
  15. Wang C. Y., Chiu C. W., Bryan G. T. Metabolism and disposition of N-(4-(5-nitro-2-furyl)-(2-14-C)thiazolyl)acetamide in the rat. Drug Metab Dispos. 1975 Mar-Apr;3(2):89–95. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES